1021869-44-2Relevant academic research and scientific papers
NOVEL PHARMACEUTICAL COMPOSITIONS
-
Paragraph 0121-0122, (2022/01/12)
The present disclosure relates to novel pharmaceutical compositions for active pharmaceutical ingredients subject to first pass metabolism. More particularly, bumetanide analogs, including bumetanide dibenzylamide, bumetanide diethylamide, and bumetanide morpholinoamide, are demonstrated as susceptible to first pass metabolism, thereby prompting effort toward developing an acceptable pharmaceutical formulation to provide adequate bioavailability.
BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE
-
Page/Page column 263, (2010/08/08)
The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl- co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.
AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE
-
Page/Page column 58-59, (2008/12/05)
Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.
